Publication | Open Access
Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
23
Citations
9
References
2022
Year
Translational MedicineAutoimmune DiseaseDisease ProgressionNeurological DisorderNatalizumab CessationNeurologyMultiple SclerosisOcrelizumab Versus FingolimodMedicineNeuroimmunology
| Year | Citations | |
|---|---|---|
Page 1
Page 1